Cardiff Oncology falls 19% on plans to drop prostate cancer programs

seekingalpha2022-09-13

The shares of clinical-stage biotech Cardiff Oncology (NASDAQ:CRDF) shed ~19% in pre-market trading Tuesday after the company announced plans not to allocate further funding for its clinical studies ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

Lady_sasa___
2022-12-06
Lady_sasa___
y
Lady_sasa___
2022-12-06
Lady_sasa___
D西安车站z swazzzsz

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2267530933?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2022-09-13 20:57","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2267530933","market":"us","top_or_hot":-1,"title":"Cardiff Oncology falls 19% on plans to drop prostate cancer programs","media":"seekingalpha","content":"<div>\n<p>The shares of clinical-stage biotech Cardiff Oncology (NASDAQ:CRDF) shed ~19% in pre-market trading Tuesday after the company announced plans not to allocate further funding for its clinical studies ...</p>\n\n<a href=\"https://seekingalpha.com/news/3882308-crdf-stock-falls-on-plans-to-drop-prostate-cancer-programs\">网页链接</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cardiff Oncology falls 19% on plans to drop prostate cancer programs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCardiff Oncology falls 19% on plans to drop prostate cancer programs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-13 20:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3882308-crdf-stock-falls-on-plans-to-drop-prostate-cancer-programs><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The shares of clinical-stage biotech Cardiff Oncology (NASDAQ:CRDF) shed ~19% in pre-market trading Tuesday after the company announced plans not to allocate further funding for its clinical studies ...</p>\n\n<a href=\"https://seekingalpha.com/news/3882308-crdf-stock-falls-on-plans-to-drop-prostate-cancer-programs\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRDF","symbol_name":"Cardiff Oncology, Inc.","start_time":0,"source_url":"https://seekingalpha.com/news/3882308-crdf-stock-falls-on-plans-to-drop-prostate-cancer-programs","article_id":"2267530933","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2267530933","pubTimestamp":1663073828,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"The shares of clinical-stage biotech Cardiff Oncology (NASDAQ:CRDF) shed ~19% in pre-market trading ","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRDF":"Cardiff Oncology, Inc.","BK4139":"生物科技"},"translate_title":"卡迪夫肿瘤学因计划放弃前列腺癌项目而下降19%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRDF":1},"content_text":"The shares of clinical-stage biotech Cardiff Oncology (NASDAQ:CRDF) shed ~19% in pre-market trading Tuesday after the company announced plans not to allocate further funding for its clinical studies in metastatic castrate-resistant prostate cancer (mCRPC). The decision followed a strategic review of clinical data and the current and projected therapeutic landscape for the indication, the company said, noting plans to reprioritize efforts on metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC). Given the unmet medical need and market opportunity in mCRC and mPDAC and the company’s results for the indications, “we will be focusing our resources on these programs and will not independently fund future clinical activities in prostate cancer,” Chief Executive Mark Erlander said. CRDF also announced plans to start a randomized Phase 2 trial for its lead asset Onvansertib in patients with KRAS-mutated mCRC in a second-line setup. The trial designed to test onvansertib in combination with standard-of-care (SoC) FOLFIRI/bevacizumab is expected to generate topline data in 2H 2024. Highlighting initial data from the Phase 2 trial in second-line mPDAC, CRDF said that 4 out of 5 evaluable patients in the ongoing open-label study achieved disease control and remained on treatment as of the data cutoff date. The fifth evaluable patient has discontinued the study due to progressive disease. The study was designed to evaluate onvansertib in combination with nanoliposomal irinotecan and 5-FU in second-line metastatic PDAC. More data from the study are expected in Q2 or Q3 2023. Updating on its liquidity level, CRDF said that its current cash resources would be adequate to fund operations into 2025. The pipeline update comes a day after CRDF added ~11% Monday in reaction to the company’s presentation at the ESMO Congress 2022 on Phase 1b/2 data for Onvansertib in patients with KRAS-mutated mCRC in a second-line setup.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":629354028,"gmtCreate":1670299191465,"gmtModify":1670300332918,"author":{"id":"3542166693292278","authorId":"3542166693292278","name":"Lady_sasa___","avatar":"https://static.tigerbbs.com/e6fdbe258f87692c4cdcd5ea6cd1032d","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"y","listText":"y","text":"y","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/629354028","repostId":2267530933,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":629355728,"gmtCreate":1670299134065,"gmtModify":1670300329655,"author":{"id":"3542166693292278","authorId":"3542166693292278","name":"Lady_sasa___","avatar":"https://static.tigerbbs.com/e6fdbe258f87692c4cdcd5ea6cd1032d","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"D西安车站z swazzzsz","listText":"D西安车站z swazzzsz","text":"D西安车站z swazzzsz","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/629355728","repostId":2267530933,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":0,"commentSize":2,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2267530933"}